Search research articles
Contact Us
Filters
Showing results (211-220 of 217) with videos related to
Page
of 22
Sort By:
You have reached the last page of results.
This site can display upto 217 results.
Nature Communications
|
February 6, 2019
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Yibo Xue, Brian Meehan, Elizabeth Macdonald, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Bulletin Du Cancer
|
March 10, 2019
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]
Vincent Lavoue, Cyrille Huchon, Cherif Akladios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Antonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2022
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial
Cathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Page
of 22
Search research articles
Search
Showing results (211-220 of 217) with videos related to
Sort By:
Page
of 22
You have reached the last page of results.
This site can display upto 217 results.
Nature Communications
|
February 6, 2019
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Yibo Xue, Brian Meehan, Elizabeth Macdonald, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Nature Communications
|
May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Bulletin Du Cancer
|
March 10, 2019
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]
Vincent Lavoue, Cyrille Huchon, Cherif Akladios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Antonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2022
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial
Cathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Page
of 22